US Edition
Published • loading... • Updated
Groundbreaking Results: Crispr Technology Halves Ldl Cholesterol and Triglycerides
Summary by medicinsketidsskrifter.dk
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CARDIOLOGICAL JOURNAL Groundbreaking results: CRISPR technology halves LDL cholesterol and triglycerides A single infusion of in vivo CRISPR/Cas9 gene therapy (CTX310) targeting the protein Angiopoietin-like protein 3 (ANGPTL3) shows a reduction in LDL cholesterol of almost 50 percent and a reduction in triglycerides of 55 percent.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
